Navigation Links
Positive Results Reported for Phase II Randomized Double-Blind Clinical Trial for the Treatment of Drug-Resistant Epilepsy Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
Date:4/28/2011

LOS ANGELES, April 28, 2011 /PRNewswire/ -- This afternoon, at the Antiepileptic Drug Trials XI Conference in Miami, Florida, (http://www.epilepsy.com/etp/aedtrialxi) Dr. Christopher DeGiorgio, principal investigator and neurologist at UCLA, presented the results of a Phase II randomized double-blind clinical trial for the treatment of refractory epilepsy.  The 50-subject study was conducted at UCLA and the University of Southern California.  "I'm excited to see that our non-invasive and very safe approach to neuromodulation demonstrates efficacy under double-blind controlled conditions and compares favorably with pharmaceutical and surgically-invasive approaches.  We look forward to proceeding to the next phase of the regulatory approval process and clinical development for our epilepsy therapies," DeGiorgio said.

This study was a randomized double-blind, active-controlled clinical trial of external TNS (eTNS™) therapy in 50 people with drug resistant epilepsy.  All subjects in the study were aged between 12 – 70 with a history of intractable seizures and exposure to at least two antiepileptic drugs at adequate doses.

The study was funded by investigator-initiated grants from the Epilepsy Therapy Project, the Epilepsy Foundation, Boston Scientific and the Milken Family Foundation.  The TNS technology, including eTNS™ for the treatment of epilepsy, was originally invented and developed at UCLA.

NeuroSigma, Inc., a Los Angeles-based medical technology company established to in-license and develop early stage technologies with the potential to transform medical practice, is the exclusive worldwide licensee of UCLA's TNS intellectual property.  "We are extremely pleased to be working closely with Dr. DeGiorgio and his talented and dedicated team at UCLA, to help make his vision of a safe, non-invasive therapy for epilepsy a reality," said Dr. Le
'/>"/>

SOURCE NeuroSigma
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Reportlinker Adds Advanced Lung Cancer with EGFR Mutation Positive Adenocarcinoma
2. Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Second Phase 3 Study in Central Retinal Vein Occlusion
3. Amgen and UCB Announce Positive Phase 2 Results of AMG 785/CDP7851 in Patients With Postmenopausal Osteoporosis (PMO)
4. Jennerex and Green Cross Announce Publication of Positive Clinical Data of JX-594 in Combination With Sorafenib in Advanced Liver Cancer
5. Merrimack Pharmaceuticals Announces that Recruitment is Open in a Phase 1 Combination Study of MM-111 with Multiple Treatment Regimens in HER2 Positive Patients
6. Columbia Laboratories and Watson Announce Publication of Positive Phase III PROCHIEVE® Vaginal Progesterone Gel Study Results
7. Jennerex and Transgene Announce the Presentation of Positive Clinical Data of JX-594 in Patients With Liver Tumors
8. Publication in SLEEP Journal Demonstrates Positive Results of Large Multi-Center Clinical Trial for Provent® Sleep Apnea Therapy
9. Analysis of Data Across Multiple Drug Eluting Stent Trials Reinforces Positive Clinical Performance of XIENCE V®
10. Positive Phase 2 Results Reported with Boehringer Ingelheims Investigational HCV Protease Inhibitor in Both Previously Treated and Untreated Patients
11. Intercept Pharmaceuticals Announces Positive Phase II Results for Obeticholic Acid (INT-747) as Monotherapy in Primary Biliary Cirrhosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 29, 2014 China Biologic Products, Inc. (NASDAQ: ... integrated plasma-based biopharmaceutical company in China ... second quarter 2014 financial results on Tuesday, August 5, ... Company,s management will hold a conference call at 8:00 ... 8:00 p.m., Beijing Time on August 6, 2014, to ...
(Date:7/29/2014)... , July 29, 2014 , ... /Oxymorphone clinical development program has commenced , ... Australia during Q4 2014 , ... States in 1H 2015 Australian drug ... on its opioid transdermal patch programs after its recent announcement of ...
(Date:7/29/2014)... ROCKLAND, Massachusetts , July 29, 2014 ... an international Phase II study investigating the efficacy and safety ... mMCC is a rare and aggressive skin cancer ... explored in a seven cohort Phase I clinical trial for ... patients  , EMD Serono, Inc., a subsidiary of ...
Breaking Medicine Technology:China Biologic to Report Second Quarter 2014 Financial Results 2China Biologic to Report Second Quarter 2014 Financial Results 3Phosphagenics Provides Update on Opioid Patch Program 2Phosphagenics Provides Update on Opioid Patch Program 3Phosphagenics Provides Update on Opioid Patch Program 4Phosphagenics Provides Update on Opioid Patch Program 5Phosphagenics Provides Update on Opioid Patch Program 6EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 2EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 3EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 4EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 5
... First Extensive Report of Bile Acid Aberration in Type 2 Diabetes ... ... N.J., June 9 /PRNewswire-FirstCall/,-- KineMed, Inc., and Daiichi Sankyo, Inc., announced ... people with type 2,diabetes which may suggest a newly identified underlying ...
... 9 Pharmacyclics, Inc.,(Nasdaq: PCYC ) today ... orally available, selective inhibitor of Bruton,s tyrosine,kinase, or ... model,for rheumatoid arthritis (RA). The data were presented ... being held this,week in Boston, MA., Researchers ...
Cached Medicine Technology:New Discovery of Key Difference in Bile Acid Metabolism in Patients with Type 2 Diabetes May Suggest Underlying Disorder 2New Discovery of Key Difference in Bile Acid Metabolism in Patients with Type 2 Diabetes May Suggest Underlying Disorder 3New Discovery of Key Difference in Bile Acid Metabolism in Patients with Type 2 Diabetes May Suggest Underlying Disorder 4New Discovery of Key Difference in Bile Acid Metabolism in Patients with Type 2 Diabetes May Suggest Underlying Disorder 5New Discovery of Key Difference in Bile Acid Metabolism in Patients with Type 2 Diabetes May Suggest Underlying Disorder 6New Discovery of Key Difference in Bile Acid Metabolism in Patients with Type 2 Diabetes May Suggest Underlying Disorder 7Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma 2Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma 3Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma 4
(Date:7/29/2014)... TN (PRWEB) July 29, 2014 The ... the reimbursement model of all hospitals. Studies show that ... One simple, easy, low cost tool that great ... performance by 20 to 25%. , Their secret? Debriefing ... one anther at the end of an operational event. ...
(Date:7/29/2014)... to a more streamlined process for obtaining stem cells, which ... tissue for failing body parts, according to UC San Francisco ... Cell . , The work builds on a strategy ... in which they again have the potential to become any ... may soon increase thanks to the scientists, identification of biochemical ...
(Date:7/29/2014)... 2014 On Friday, the United States ... week of October 12-18, 2014, as "National Case Management ... improving healthcare outcomes for patients. The resolution was introduced ... (R-AR), with support by the Case Management Society of ... case management professionals for their contributions to healthcare. , ...
(Date:7/29/2014)... July 29, 2014 The Eleventh Annual ... Summit concluded with the $10,000 prize being presented to ... http://www.bikanta.com ) , The 11th Annual Summit was held ... entrepreneurs who can bring innovative products and services for ... pleased to have had such excellent array of young ...
(Date:7/29/2014)... Lean and Lovely, an affordable and short program, claims ... wear a bikini in the near future. This has caught ... , “Our Lean and Lovely review shows that ... levels. Neither your age nor your body shape matters, which ... the beginning, you will achieve the results that you have ...
Breaking Medicine News(10 mins):Health News:One Brilliant Economic Survival Tool You Can Steal from the World's Best Hospitals 2Health News:One Brilliant Economic Survival Tool You Can Steal from the World's Best Hospitals 3Health News:Stem cell advance may increase efficiency of tissue regeneration 2Health News:Stem cell advance may increase efficiency of tissue regeneration 3Health News:CMSA Supports National Case Management Week Resolution Introduced in US Senate 2Health News:Silicon Valley Boomer Venture Summit Names Bikanta Competition Winner 2Health News:Lean and Lovely: Review Examining Neghar Fonooni’s Program Released 2
... WASHINGTON, July 9 The Pharmaceutical Care,Management Association ... the Medicare bill, which includes a provision that ... "The inclusion of an e-prescribing requirement in ... a patient,s perspective, e-prescribing,is the most important issue ...
... Protect Patient Access To Community,Pharmacies, ALEXANDRIA, ... voted by unanimous consent in favor of ... Providers Act of 2008 contains three critical,provisions ... D claims, delayed cuts to Medicaid generic ...
... patients with the blood cancer , , WEDNESDAY, July 9 ... once-banned drug thalidomide for patients with myeloma have learned ... is to science: Don,t judge results too early. , ... increased the odds of a complete remission, but not ...
... Counseling for All Combat Veterans, WASHINGTON, July 9 ... in 39 additional,communities across the country where the Department ... 2009., "Community-based Vet Centers -- already in all ... health program," said Dr. James B. Peake,Secretary of Veterans ...
... body,s ability to repair sperm DNA, studies find , , ... over- or underweight can have a negative effect on ... to be presented July 9 at the annual conference ... in Barcelona, Spain. , While semen samples from diabetics ...
... Ind., July 9 Zimmer Holdings, Inc.,(NYSE and SWX: ... conference call will be broadcast live over the Internet ... A news release,detailing the quarterly results will be made ... The live audio webcast can be accessed via ...
Cached Medicine News:Health News:Thalidomide Continues to Show Benefits Against Myeloma 2Health News:Thalidomide Continues to Show Benefits Against Myeloma 3Health News:VA Vet Centers Coming to 39 Communities 2Health News:Diabetes, Weight Tied to Male Infertility 2
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
Finesse II electrosurgical generator (100-120 VAC) utilizes a patented design that integrates the electrosurgical generator and smoke evacuation system into a single compact unit....
Finesse electrosurgical generator (100-120 VAC) utilizes a patented design that integrates the electrosurgical generator and smoke evacuation system into a single compact unit....
The Aaron 800-EU is designed and engineered to be the most reliable and durable desiccator available today....
Medicine Products: